Through this collaboration, RetinaLyze’s clinically validated AI technology for detecting signs of diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma will be integrated directly into Medibrix’s comprehensive digital healthcare ecosystem. This enables healthcare providers using Medibrix to offer rapid, reliable eye screenings to their patients, helping to identify sight-threatening conditions at an early stage.
"By integrating RetinaLyze into the Medibrix platform, we are taking another step toward offering our users a complete and efficient healthcare experience," said Marius Christensen, CEO & Managing Director of Medibrix. "Eye health is an essential but often overlooked part of preventive healthcare. This cooperation allows us to empower clinicians with tools that make early detection easier and more accessible than ever."
Teddy Petersen, CEO of RetinaLyze System A/S, added: "We are excited to work with Medibrix to bring our AI-driven eye screening technology to an even wider audience. Medibrix shares our vision of making healthcare more proactive, and through this collaboration, we can jointly contribute to better eye health outcomes and improved patient care across multiple healthcare settings."
The integration is available soon, offering Medibrix users seamless access to RetinaLyze’s capabilities within their familiar workflow. Both companies look forward to expanding the scope of their cooperation in the future, delivering further innovation at the intersection of digital health and AI.
Medibrix (formerly Helseboka) is a leading digital health platform offering a wide range of solutions to optimize healthcare delivery, streamline workflows, and enhance patient engagement. Learn more at www.medibrix.com.
RetinaLyze develops and delivers AI-driven software solutions for eye screening, helping healthcare providers detect eye diseases early with greater accuracy and efficiency. Learn more at www.retinalyze.com.
